baber/WOPTO huggingface dataset:
Patent NZ-533876-A (NZ)
Title: Improvements in/or relating to sliding doors
Inventor: BURGGRAAF DAVID
Filed: 2004-06-30
Abstract: A sliding door or window assembly comprises a frame of at least a head frame member and a sill frame member to provide a frame defined opening. At least one sliding panel is mounted by load bearing elements at atleast two points to the head frame member. It is further engaged in sliding engagement with the sill frame member via a sill running track extending along the sill frame member and that is defined between sill upper and lower regions at an undercut. The sliding panel includes at least one bottom runner engaged with the running track, which allows guided sliding of the sliding panel parallel to the part frame opening. But it also substantially prevents movement perpendicular to the plane of the opening.
Patent NZ-535897-A (NZ)
Title: Process and system for removal of solvent (such as light organic solvent preservative) from timber
Inventor: SNOAD HOWARD
Filed: 2004-10-12
Abstract: A process for the removal of solvent from treated timber is described. The timber, treated with agents selected from insecticides, flame retardants and preservatives, is exposed to a reduced pressure and a source of radio frequency energy. The solvent is disclosed to be any substance normally a liquid at room temperature and pressure, an organic or light organic solvent. An apparatus is also described to be used in the removal of solvent from timber which comprises: - a chamber capable of withstanding a reduced internal pressure and having means therein for the passage of timber to be treated through at least one opening in the chamber; and - one or more radio frequency energy sources.
Patent NZ-537833-A (NZ)
Title: Compositions and methods for VEGF siRNA inhibition of angiogenesis
Inventor: TOLENTINO MICHAEL J
IPC: A61K38/00
Filed: 2003-07-18
Abstract: Disclosed is an isolated siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA. The siRNA are useful for treating diseases or conditions involving angiogenesis.
Patent NZ-538082-A (NZ)
Title: Ambient light auto-zero circuit for photo-optical physiological monitoring equipment
Inventor: SPARKS CHRISTOPHER BRYN
Filed: 2005-02-04
Abstract: A power reduction circuit adapted to be used to measure one or more physiological properties of a patient at preset intervals by illuminating a portion of the patient with one or more light sources, which produces a reflected or transmitted modified light signal representative of the physiological property being measured; the modified light signal is detected by a photo-sensor which produces a raw output signal, which includes an ambient light component, that is representative of the modified light signal, characterised in that the power reduction circuit includes: (i) an adding unit adapted to produce a processed signal by adding the raw output signal to a second signal; (ii) a first signal buffer adapted to retain the processed signal; (iii) a processing unit which further processes the processed signal; (iv) an isolating switch which is controlled by the processing unit and is connected to the first signal buffer, said isolating switch being adapted to reversibly connect the first signal buffer to a feed back circuit; (v) said feedback circuit is adapted to generate the second signal from the processed signal, and includes a second signal buffer, which is adapted to retain the level of the processed signal inside the feedback circuit, and an inverting amplifier, which amplifies and inverts the processed signal in the second signal buffer generating the second signal; wherein the processed signal generated when the isolating switch is open, during the measurement of the desired physiological property, is effectively free of the ambient light component.
Patent NZ-545365-A (NZ)
Title: Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases
Inventor: WARD WARREN
IPC: A61K9/50
Filed: 2004-07-19
Abstract: The disclosure relates to medically efficacious substances coated with an agent that forms a liquid impermeable but gas permeable layer, the treatment of medical conditions therewith, and particularly medical conditions at least partially characterised by blockage or other malfunction of ducts of exocrine glands and especially ducts of sweat glands. Particularly disclosed a medicament composition comprising one or more medically efficacious substances (such as sodium chloride, capsaicin, metformin, salicylic acid, and a derivative of salicylic acid) coated by an agent (such as a ceramic, a polymer and a natural wax particularly beeswax hardened with cornstarch and talc) that forms a liquid impermeable but gas permeable layer surrounding the substance(s) and preventing the passage of the substance(s) therethrough, the composition being further characterized in that in use said efficacious substance(s) is/are not released into solution in the body. A patch adapted for adherence to skin comprising said composition and a device comprising a holder adapted to house said composition comprising said composition, an energy source and an actuator driven by the energy source for temporarily and at intervals placing the said composition on the skin of a subject is also disclosed.
Patent NZ-546043-A (NZ)
Title: Dianhydrohexite mononitrate derivatives of cyclic sugars and uses thereof
Inventor: REPOLLES MOLINER JOSE
IPC: C07D493/04
Filed: 2004-09-29
Abstract: Disclosed are derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof; wherein the substituents are defined within the specification, as well as pharmaceutical compositions comprising these compounds and uses thereof for the manufacture of a pharmaceutical composition for the prevention and/or treatment of atherosclerosis, endothelial dysfunctions, vasospasm, cardiac allograft vasculopathy, platelet activation, thrombosis, stroke, pathological conditions where oxidative stress plays a role in their pathogenesis, pathological conditions where a deficit of nitric oxide plays a role in their pathogenesis, and/or tissue damage due to ischemia and/or due to ischemiareperfusion.
Patent NZ-548978-A (NZ)
Title: Hybrid polypeptides with selectable properties
Inventor: LEVY ODILE ESTHER
IPC: C07K14/575
Filed: 2005-02-11
Abstract: Provided is a hybrid polypeptide exhibiting at least two hormonal activities, said hybrid polypeptide comprising a first bio-active peptide hormone module covalently linked to at least one additional bio-active peptide hormone module; wherein: the bio-active peptide hormone modules are independently selected from the group consisting of: component peptide hormones, fragments of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of the component peptide hormones, and fragments of analogs and derivatives of component peptide hormones that exhibit at least one hormonal activity of theÀ component peptide hormones; the component peptide hormones are independently selected from at least two of the group consisting of: amylin and exendin-4; and both of the bio-active peptide hormone modules exhibits at least one hormonal activity of a component peptide hormone.
Patent NZ-550583-A (NZ)
Title: Thio-substituted arylmethanesulfinyl derivatives
Inventor: LESUR BRIGITTE
IPC: C07C323/16
Filed: 2005-04-13
Abstract: Disclosed is a thio substituted arlymethanesulfinyl compound of formula (A) wherein the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (A) in the manufacture of a medicament for treatment of a neurological disease or disorder selected from Parkinson's disease; Alzheimer disease; attention deficit disorder; attention deficit disorder; attention deficit hyperactivity disorder; depression; and fatigue associated with a neurological disease or disorder.
Patent NZ-554717-A (NZ)
Title: A movement assembly with work articles movable on threaded drive shaft by shaft rotation
Inventor: DAVIES PETER OWEN
IPC: B65B25/02
Filed: 2007-04-24
Abstract: A movement assembly including a drive axle (21); a number of threaded drive portions (22) operativeIy associated with the axle; two or more work articles (12) positioned in a row aligned with the longitudinal axis of the drive axle; at least one work article having a complimentary thread (18) engaged with an associated drive portion; characterised in that the movement assembly is configured such that rotation of the drive axle causes the threaded drive portions to turn and alter the spacing between the engaged work articles along the row. At least one threaded drive portion is also coupled to a work article adjacent to that which it is associated.
Patent NZ-555612-A (NZ)
Title: Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
Inventor: HARATS DROR
IPC: A61K38/17
Filed: 2005-11-14
Abstract: Use of a nucleic acid construct comprising (a) a cis regulatory element including a polynucleotide having the sequence set forth in SEQ ID NO:8 and at least one copy of the sequence as set forth in SEQ ID NO: 6; (b) an endothelial cell promoter; and (c) a polynucleotide sequence encoding a cytotoxic polypeptide comprising the extracellular region of TNFRI and the trans-membrane and intracellular regions of Fas cytotoxic polypeptide; for the manufacture of a medicament for inhibiting angiogenesis in a subject in need thereof; wherein said subject is being treated with an additional chemotherapeutic modality.
Patent NZ-556574-A (NZ)
Title: Trigger assembly for a power tool
Inventor: GALLAGHER WILLIAM F
Filed: 2006-05-05
Abstract: A trigger assembly is disclosed for a power tool having a motor disposed within a housing. The trigger assembly comprises a switch disposed within the housing for activating the motor, and trigger extending from the housing and engageable by a user. The trigger has a front portion and a link member and being siideably moveable between a rearward position and a forward position. The trigger assembly is arranged such that when the trigger is in its forward position, the link member engages the switch to operate the motor and the front portion is pivotably movable towards the housing to engage the housing and thereby to lock the trigger in its forward position. When the trigger is in its rearward position, the link member is disengaged from the switch, such that the motor is turned off, and the head portion is not pivotably engageable with the housing.
Patent NZ-561554-A (NZ)
Title: A bath
Inventor: MURPHY PETER
IPC: A47K3/02
Filed: 2007-09-14
Abstract: A removable cover component 7 for a bath, having one cover part which when the cover is in place in a bath can sit over a drain outlet of the bath and having on an underside an integral plug 14 which closes the drain outlet, having and another larger cover part which is cranked relative to the first cover part and is larger than the one cover part and which when the cover is in place in a bath can extend up a wall section of the bath adjacent the drain outlet towards a rim of the bath to assist in supporting a person sitting in the bath over or adjacent the drain outlet and reclining against the wall of the bath.
Patent NZ-564621-A (NZ)
Title: Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
Inventor: SIEGER PETER
IPC: A61K31/4184
Filed: 2006-06-01
Abstract: Disclosed herein aer polymorphs of ethyl 3-[2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, processes for the preparation thereof and the use thereof as pharmaceutical compositions.
Patent NZ-568292-A (NZ)
Title: Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
Inventor: JITSUOKA MAKOTO
IPC: A61P25/02
Filed: 2006-11-10
Abstract: Disclosed are spiro[cyclohexane-1,1'-(3'H)-azaisobenzofuran]-4-carboxamide derivatives as represented by the general formula (I), where R is represented by the general formula (II-1). Of particular importance are the compounds trans-5'-methoxy-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide; trans-5'-methoxy-3'-oxo-N-methyl-N-(2-pyrrolidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide; trans-4'-methoxy-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-5'-azaisobenzofuran]-4-carboxamide; trans-4'-methyl-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-5'-azaisobenzofuran]-4-carboxamide; trans-4'-(1-methyl-1H-pyrazol-4-yl)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)spiro[cyclohexane-1,1'-(3'H)-5'-azaisobenzofuran]-4-carboxamide; and trans-5'-pyrazinyl-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide; or a pharmaceutically acceptable salt thereof. Further disclosed is the use of a compound as defined above for the manufacture of a medicament for treating or preventing: metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, and fatty liver; circulatory system diseases such as stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy and electrolyte abnormality, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic aeromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, depression, anxiety, epilepsy, delirium, dementia, schizophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, cognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, drug dependency, alcoholism, and tremor.
Patent NZ-573052-A (NZ)
Title: Hepatitis c virus infection biomarkers
Inventor: RAMACHANDRAN RAVI K
IPC: C07H21/04
Filed: 2007-04-25
Abstract: Disclosed is a method of evaluating a subject, the method comprising: determining the expression levels of the genes in a signature set of genes in the subject, wherein the signature set of genes comprises one or more interferon-sensitive genes(ISG) selected from the group consisting of IFIT1, RSAD2, IFIT2, IFIT6, IFI44, IFIT5, PLSCR1, IFIT3, IFI35, IFITM1, IFITM3, IFI30, IFITM2, GIP2, OAS3, MX1, IFIL44L, IFI27, IFIT2A, PRSAD, or IFITA, wherein the signature set has the following properties: it includes a plurality of genes each of which is differentially expressed as between virally infected individuals and non-infected individuals, and the differential expression is predictive of infection with no more than about 15% false positives; and comparing the expression level of each of the genes in the set from the subject with a reference value, thereby evaluating the subject, wherein the reference value is either: (i) a non-infected reference and wherein differential expression of each of the genes in the signature set of genes indicates a first state, and differential expression of less than all of the genes in the signature set indicates a second state; or (ii) an infected reference and wherein non-differential expression of each of the genes in the signature set of genes indicates a first state, and non-differential expression of less than all of the genes in the signature set indicates a second state, wherein the evaluating occurs prior to, during the course of, or after administering an inhibitor of a viral protease to the subject, and wherein the evaluation of the expression of the genes in a signature set of genes is performed on an isolated sample from the subject.
Patent NZ-573504-A (NZ)
Title: Herbicidal formulations for combinations of dimethylamine and potassium salts of glyphosate
Inventor: YERITSYAN KAREN
IPC: A01N33/12
Filed: 2008-12-10
Abstract: A high strength herbicidal composition comprising: (a) water, (b) glyphosate, predominantly in the form of a combination of dimethylamine salt and potassium salt, in solution in the water in an amount of about 350 grams or greater of acid equivalent per liter of the composition, wherein the composition is formulated to include dimethylamine in an amount to form a salt with about 5% or greater, by weight, of total glyphosate and to include potassium in an amount to form a salt with a percentage of total glyphosate so that the combined sum of glyphosate in dimethylamine and potassium salts is at least 45% of total glyphosate, and (c) optionally, one or more surfactants and/or one or more humectants.
Patent NZ-576993-A (NZ)
Title: Polyurethane adhesive comprising an acrylic layer with isocyanate groups and a layer containing isocyanates
Inventor: JANOWICZ ANDREW
IPC: C08G18/00
Filed: 2007-10-31
Abstract: Disclosed is method for manufacturing an article, comprising: (a) formulating an acrylic composition having a multifunctional chain transfer agent, wherein said multifunctional chain transfer agent comprises an isocyanate-reactive group; and (b) bonding a layer of the acrylic composition with a layer of an isocyanate-containing composition to form a bond, by reacting at least a portion of the multifunctional chain transfer agent with the isocyanate-containing composition. Also disclosed are articles manufactured according to the method, i.e., articles comprising a layer of an acrylic composition having bound therein at least one residue of a multifunctional chain transfer agent, wherein the multifunctional chain transfer agent residue comprises a reacted isocyanate-reactive group that has been reacted to an isocyanate within a layer of an isocyanate-containing composition.
Patent NZ-583032-A (NZ)
Title: Phenyl-cyclopropanecarboxylic acid derivatives
Inventor: NAGASE TOSHIHIKO
IPC: A61P11/02
Filed: 2008-08-11
Abstract: Disclosed are phenyl-cyclopropanecarboxylic acid derivatives represented by formula (Ia), wherein the substituents are as defined in the specification. These compounds are suitable for use in the prevention and/or treatment of a disease mediated by a DP receptor, wherein the disease mediated by the DP receptor includes allergic disease, systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, acne, allergic bronchial pulmonary aspergillosis, sinusitis, migraine, nasal polypus, anaphylactic vasculitis, eosinophilic syndrome, contact dermatitis, diseases accompanied by itch, diseases generated secondarily as a result of behavior accompanied by itch, diseases accompanied by flushing, inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, autoimmune disease, traumatic brain disorder, hepatopahty, graft rejection, chronic rheumatoid arthritis, pleurisy, osteoarthritis, Crohn's disease, ulcerative colitis, irritable bowel syndrome, interstitial cystitis, muscular dystrophy, polymyositis, cancer, leukemia, viral infection, multiple sclerosis, sleeping disorders, or disease associated to platelet aggregation.
Patent NZ-586504-A (NZ)
Title: An apparatus for forming an underground tunnel
Inventor: LUMB MATTHEW
IPC: E21D9/087
Filed: 2008-12-17
Abstract: The present disclosure provides an apparatus for forming an underground tunnel. The apparatus comprises a cutting head for removing material from a wall portion of the tunnel and thereby forming a portion of the tunnel. Further, the apparatus comprises a support structure for supporting a previously formed portion of the tunnel. The support structure is arranged to provide a supporting force against a surface of the tunnel when stationary and when being moved along the tunnel. Further, the apparatus comprises a conveyor for conveying removed material from the cutting head to a location remote from the cutting head during formation of the portion of the tunnel.
Patent NZ-587431-A (NZ)
Title: Reinforcement rib for an arch with the rib having planar side and top walls and lower flange
Inventor: WILSON MICHAEL W
IPC: E04C5/01
Filed: 2009-02-19
Abstract: A reinforcement rib 82, 82', 82'' for an arch-type structure 60 comprises a pair of generally planar sidewalls, a generally planar top wall bridging the tops of the sidewalls, and a generally planar lower flange extending outwardly from the bottom of each sidewall and being generally parallel to the top wall. Each lower flange has a concave undersurface that has a shape complimentary to an underlying surface of the arch-type structure 60. The sidewalls are angled inwardly in a direction towards the top wall. The rib 82, 82', 82'' has a longitudinal dimension substantially greater than its transverse dimension, is longitudinally curved, is substantially twist free and is of a roll-formed construction.
Patent NZ-591813-A (NZ)
Title: Cell culture device comprising a porous membrane and a hydrophobic barrier
Inventor: STOPPINI LUC
IPC: C12M1/12
Filed: 2009-08-21
Abstract: Disclosed is a device for cell culture, said device comprising: (i) a medium conduit having one open end and one end closed by a porous membrane fused across it; and (ii) a frame holding the medium conduit in a substantially vertical orientation; wherein the medium conduit is adapted to permit retention by capillarity of a sufficient volume of liquid culture medium in the medium conduit to contact the surface of the porous membrane and thus supply nutrients to cells that may be grown on the porous membrane, characterised in that the surface of the membrane contralateral to the surface of said porous membrane sealed to said medium conduit comprises a hydrophobic barrier adapted to contain the culture.
Patent NZ-602075-A (NZ)
Title: Abuse-resistant formulations
Inventor: KRALING CARRIE
IPC: A61K9/26
Filed: 2011-02-23
Abstract: 602075 Provided is a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix which contains a viscosity modifier in an amount from about 1 to about 10 percent by weight of the dosage form selected from sodium alginate, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, crosslinked polyacrylic acid, gelatin, pectins, gums, polyethylene oxides, Konjac flour, carrageenan, xanthan gum, and mixtures thereof and comprises coated granules containing hydrocodone, wherein the core of the coated granules contains less than 5% fat/wax. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance